P344 Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study. (25th January 2019)

• Record Type: Journal Article
• Authors: Ungaro, R; Fenster, M; Dimopoulos, C; Patel, A; Deepak, P; Syal, G; Yarur, A; Hirten, R; Christophi, G; Khatiwada, A; Lin, B; Colombel, J-F; Ha, C; Weisshof, R; Beniwal-Patel, P; Cohen, B; Pekow, J
• Is Part Of: Journal of Crohn's and colitis. Volume 13(2019)Supplement 1
• Page Start: S274
• Page End: S275
• Publication Date: 2019-01-25
• Subjects: Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjy222.468
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: Background: We aimed to describe the real-world effectiveness of tofacitinib in ulcerative colitis (UC). Methods: We analysed a retrospective, multi-centre cohort from six centres in the USA. UC patients started on tofacitinib (10 mg BID) for active disease were included. Primary outcome was clinical response (>50% reduction in symptoms) at Week 8 as determined by physician global assessment. Secondary outcomes included clinical remission (no symptoms) at Week 8, clinical response/remission at Week 16 and endoscopic healing (defined as Mayo endoscopic score ≤1 or absence of erosions/ulcerations) within 6 months of initiating tofacitinib. Descriptive statistics and Fisher exact tests were performed. Logistic regression assessed predictors of Week 8 response. A multi-variable model was created using backward elimination. Results: A total of 123 UC patients were included with a median age of 38 years (IQR 27–46) and 5 years disease duration (IQR 2–9). 56.1% were men and 60.2% had pancolitis. 28.5% were bio-naïve while 40.7% had been exposed to both anti-tumour necrosis factor (anti-TNF) biologics and vedolizumab (VDZ). Ninety-six patients completed 8 weeks of tofacitinib. 60.8% had clinical response and 13.5% clinical remission at Week 8. At Week 16 (total n = 74), 55.4% had clinical response and 48.6% clinical remission. 64.9% (total n = 57) had endoscopic healing. A larger proportion of bio-naïve patients achieved clinical response with no difference between those exposed to both anti-TNF and VDZ or either alone (Table 1). Patients with prior exposure to 2 biologic classes (anti-TNF and VDZ) had lower rates of endoscopic healing compared with bio-naïve and 1 biologic class exposure (Table 1). Bio-naïve status and higher albumin were associated with greater chance of Week 8 response while pancolitis, baseline endoscopic Mayo score 3, concomitant steroids at start of tofacitinib, and male gender were associated with lower chance of response (Table 2). In multi-variable analysis, bio-naïve status (aOR 5.50, 95% CI 1.71–17.65), concomitant steroids (aOR 0.25, 95% CI 0.07–0.83), and male gender (aHR 0.25, 95% CI 0.08–0.83) were associated with Week 8 response. Conclusions: Tofacitinib is effective at inducing clinical response in a real-world clinical setting. Prior exposure to biologics is associated with reduced chance of clinical response and endoscopic healing.